News Roche to file Actemra in inflamed artery disease Drug successful in late stage trial for giant cell arteritis
News Novartis drug gets fast US review in AML Midostaurin also under review in rare disease systemic mastocytosis
News Ipsen charts $1.75bn course for Kartos acquisition Ipsen has agreed to buy cancer biotech Kartos Therapeutics for $450m upfront, adding a late-stage drug in the challenging MDM2 inhibitor class.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
